India's revised Schedule M regulations are pushing pharmaceutical manufacturers towards higher quality standards, but many small and medium-sized units face significant challenges in compliance. Can a Rajan-style NRI dollar-deposit scheme save the rupee? Down 30% in 1 year, are AI-hit Infy, TCS still value stocks? Is Air India the cocktail turning bitter for Tatas? Stock-linked pay for UGRO promoter raises governance concerns How practical is India’s latest investor protection framework?
